Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?-Reference-Cited by-同舟云学术

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Published:2017-05-05 Issue:1 Volume:99 Page:60-69
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Lestang Elsa¹,Peterlin Pierre¹,Le Bris Yannick²,Dubruille Viviane¹,Delaunay Jacques¹,Godon Catherine²,Theisen Olivier²,Blin Nicolas¹,Mahe Beatrice¹,Gastinne Thomas¹,Garnier Alice¹,Touzeau Cyrille¹,Voldoire Maud¹,Bene Marie C.²,Le Gouill Steven¹,Milpied Noel¹,Mohty Mohamad¹,Moreau Philippe¹^ORCID,Guillaume Thierry¹,Chevallier Patrice¹^ORCID

Affiliation:

1. Hematology Department; CHU Hotel-Dieu; Nantes France

2. Hematology/Biology Department; CHU Hotel-Dieu; Nantes France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12891/fullpdf

Reference48 articles.

1. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet;Barbui;J Clin Oncol,2011

2. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting;Klyuchnikov;Br J Haematol,2012